Highlights
- Dr. Reddy's Laboratories shares rose nearly 1% during the morning trading session on July 8.
- The stock has outperformed the Nifty 50 across one-month, year-to-date and one-year periods.
- The company reported consolidated profit while standalone results reflected a quarterly net loss for March 2026.
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) traded higher in early trading on July 8, with the stock gaining 0.92% to INR 1,367.00.
The stock opened at INR 1,357.00 and advanced to an intraday high of INR 1,383.00, while the session low remained at the opening price. It had closed at INR 1,354.60 in the previous session, and the volume-weighted average price (VWAP) stood at INR 1,373.73.
Trading Activity and Market Snapshot
Around 4.44 lakh shares changed hands during the session, resulting in a traded value of approximately INR 60.93 crore. The order book showed 40.78% buy quantity compared with 59.22% sell quantity, indicating relatively higher sell orders during the trading session.
Dr. Reddy's Laboratories had a total market capitalisation of INR 1.14 lakh crore, while its free-float market capitalisation stood at INR 83,139.89 crore. The stock is a constituent of the Nifty 50 index and operates in the pharmaceutical industry. It trades under the EQ series with T+0 settlement.
Stock Performance Across Timeframes
Dr. Reddy's Laboratories has delivered positive returns across multiple investment periods. The stock gained 2.10% over the past week and 7.24% during the last month, outperforming the Nifty 50, which returned 0.92% and 4.78%, respectively.
On a year-to-date basis, the stock has advanced 9.14%, while the Nifty 50 has declined 7.34%. Over the past year, Dr. Reddy's Laboratories has returned 6.56%, compared with a 5.07% decline in the benchmark index. Over three years, the stock has gained 31.98%, while its five-year return stands at 25.12%.
Source: Analysis by Kalkine
FY26 March Quarter Financial Results
For the quarter ended March 31, 2026, Dr. Reddy's Laboratories reported consolidated total income of INR 8,02,180 lakh. Consolidated profit before tax stood at INR 19,510 lakh, while consolidated net profit came in at INR 22,130 lakh. Consolidated earnings per share (EPS) were INR 2.65.
On a standalone basis, total income stood at INR 4,38,920 lakh. The company reported a standalone loss before tax of INR 30,550 lakh and a standalone net loss of INR 21,940 lakh. Standalone EPS for the quarter was negative at INR 2.63. The audited standalone and consolidated financial results were released on May 12, 2026.
Valuation and Trading Metrics
Dr. Reddy's Laboratories is trading at a symbol P/E ratio of 27.28, which is also its adjusted P/E. The stock has traded within a 52-week range of INR 1,148.40 to INR 1,414.90. The 52-week high was recorded on June 29, 2026, while the 52-week low was touched on January 21, 2026.
Daily volatility stands at 1.44%, while annualised volatility is 27.51%. The applicable margin rate is 12.55%, and the deliverable quantity accounted for 54.00% of traded volume.
Key Risks
- Regulatory actions could affect manufacturing or product approvals.
- Pricing pressure may impact profitability in key markets.
- Currency movements could influence export earnings.
- Product competition may affect revenue growth and market share.
Summary
Dr. Reddy's Laboratories shares traded nearly 1% higher in early dealings on July 8, outperforming the broader market. The stock has delivered positive returns over the past week, month, year-to-date period and one year relative to the Nifty 50. For the March 2026 quarter, the company reported consolidated profitability, while its standalone financial statements reflected a net loss for the period.
FAQs
Q: What was Dr. Reddy's Laboratories' share price on July 8, 2026?
A: The stock traded at INR 1,367.00, up 0.92% from the previous closing price during the morning session.
Q: How has Dr. Reddy's Laboratories performed against the Nifty 50?
A: The stock outperformed the Nifty 50 across one-month, year-to-date and one-year performance periods.
Q: What was Dr. Reddy's Laboratories' consolidated EPS for the March 2026 quarter?
A: The company reported consolidated earnings per share of INR 2.65 for the quarter ended March 31, 2026.